eotaxintargeted

Eotaxintargeted refers to a set of therapeutic strategies aimed at inhibiting the eotaxin family of chemokines (CCL11/eotaxin-1, CCL24/eotaxin-2, CCL26/eotaxin-3) or their receptor CCR3 to limit eosinophil recruitment and activation in inflammatory diseases. Eotaxins are produced by various cells in response to inflammatory signals and act as potent chemoattractants for eosinophils through CCR3, contributing to tissue eosinophilia in conditions such as asthma, allergic rhinitis, and eosinophilic esophagitis. By blocking eotaxin signaling, eotaxintargeted therapies aim to reduce eosinophil influx, tissue damage, and disease activity.

Therapeutic approaches include monoclonal antibodies against eotaxins (targeting CCL11, CCL24, or CCL26), small-molecule CCR3 antagonists, and soluble decoy receptors that sequester eotaxins. Gene-silencing strategies and other biologics that disrupt the eotaxin-CCR3 axis have also been explored in preclinical models. Delivery methods vary by agent and can involve systemic administration or localized routes for specific diseases.

Clinical status: As of 2024, several eotaxin-targeted agents have been evaluated in preclinical and early-phase trials, but no therapy has received regulatory approval specifically for eotaxin neutralization. Results have been mixed, in part due to redundancy among chemokines and alternative pathways for eosinophil recruitment. Safety profiles are generally acceptable in the short term, but long-term effects on host defense against parasites and other infections remain an area of concern.

Eotaxintargeted remains an active area of research for eosinophilic inflammatory diseases and is often considered alongside broader anti-eosinophil strategies, including IL-5/IL-5R inhibitors, in efforts to tailor therapies to individual patient profiles.